Categories
Anticancer Drugs Obinutuzumab Oncology Pharmacology Physiotherapy

Obinutuzumab

In this article we will discuss about Obinutuzumab (Dosage Overview)

In this article, we will discuss about Obinutuzumab (Dosage Overview). So, let’s get started.

Obinutuzumab (GAZYVA) is a CD20-directed cytolytic antibody and is
indicated:
• in combination with chlorambucil, for the treatment of patients with
previously untreated chronic lymphocytic leukemia.
• in combination with bendamustine followed by Obinutuzumab (GAZYVA) monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen.
• in combination with chemotherapy followed by Obinutuzumab (GAZYVA) monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.

Dosage

• Premedicate for infusion reactions and tumor lysis syndrome.
• Dilute and administer as intravenous infusion. Do not administer as an
intravenous push or bolus.
• The dose for chronic lymphocytic leukemia is 100 mg on day 1 and 900 mg on day 2 of Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on
day 1 of Cycles 2–6.
• The dose for follicular lymphoma is 1000 mg on day 1, 8 and 15 of Cycle 1,
1000 mg on day 1 of Cycles 2-6 or Cycles 2-8, and then 1000 mg every 2 months for up to 2 years.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.